Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions

Leukemia and Lymphoma

Volumn 54, Issue 8, 2013, Pages 1640-1646

  Weide, Rudolf ^a   Feiten, Stefan ^b   Friesenhahn, Vera ^b   Heymanns, Jochen ^a   Kleboth, Kristina ^b   Thomalla, Jörg ^a   Van Roye, Christoph ^a   Köppler, Hubert ^a  

^a Praxisklinik für Hämatologie und Onkologie ^*  (Germany)

^b Institut fur Versorgungsforschung in der Onkologie   (Germany)

Author keywords

Bendamustine; CLL; NHL; Refractory; Relapsed; Retreatment

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; FOLLICULAR LYMPHOMA; GRANULOCYTOPENIA; HUMAN; LEUKEMIA RELAPSE; LEUKOPENIA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; OUTPATIENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETREATMENT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; REMISSION INDUCTION; RETREATMENT; TREATMENT OUTCOME;

EID: 84879377074     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.747679     Document Type: Article

References (28)

1. Ozegowski W, Krebs D. w -[bis-(chlorethyl)-Amino-benzimidazolyl-(2)]- propionic or butyric acids as potential cytostatic agents. J Prakt Chem 1963 ; 20 : 178-186
2. Weide R. Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin' slymphoma. Ther Clin Risk Manag 2008 ; 4 : 727-732
3. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008 ; 14 : 309-317
4. Gaul L, Mandl-Weber S, Baumann P, et al. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: The role of ATMChk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 2008 ; 134 : 245-253
5. Leoni LM, Hartley JA. Mechanism of action: The unique pattern of bendamustine-induced cytotoxicity. Semin Hematol 2011 ; 48(Suppl. 1): S12-S23
6. Kath R, Blumenstengel K, Fricke HJ, et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001 ; 127 : 48-54
7. Bergmann M A, Goebeler M E, Herold M, et a l. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica 2005: 90: 1357-1364
8. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin slymphomas. Anticancer Drugs 2001; 12: 725-729
9. Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin slymphoma: Results from a phase II multicenter, single-Agent study. J Clin Oncol 2008 ; 26 : 204-210
10. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a Multicenter Study. Cancer 2010 ; 116 : 106-114
11. Kö ppler H, Heymanns J, Pandorf A, et al. Bendamustine plus mitoxantrone-A new effective treatment for advanced chronic lymphocytic leukemia: Results of a phase I/II study. Leuk Lymphoma 2004 ; 45 : 911-913
12. Kö ppler H, Fuss H, Hurtz HJ, et al. Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): Results of a multicentre phase II study of the German CLL Study Group (GCLLSG). Br J Haematol 2012 ; 158 : 238-241
13. Weide R, Heymanns J, Köppler H. Successful treatment of alkylating agent resistant low grade B-cell non Hodgkin slymphomas with bendamustine/mitoxantrone/rituximab (BMR). Onkologie 1999; 22(Suppl.): Abstract 644
14. Weide R, Heymanns J, Gores A, et al. Bendamustine mitoxantrone and rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma 2002; 43: 327-331
15. Weide R, Pandorf A, Heymanns J, et al. Bendamustine/ mitoxantrone/ rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004; 45: 2445-2449
16. Weide R, Hess G, Kö p pler H, et a l. Highanti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48: 1299-1306
17. Weide R, Mergenthaler U, Friesenhahn V, et al. Bendamustine/ mitoxantrone/rituximab: A short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 2009 ; 50 : 1468-1474
18. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profi le in the treatment of mantle cell and low-grade non-Hodgkin slymphoma. J Clin Oncol 2005 ; 23 : 3383-3389
19. Fischer K, Cramer P, Busch R, et a l. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011 ; 29 : 3559-3566
20. Iannitto E, Morabito F, Mancuso S, et al. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: An Italian retrospective study. Br J Haematol 2011 ; 153 : 351-357
21. Cheson B D, Bennett J M, Grever M, et a l. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996 ; 87 : 4990-4997
22. Cheson BD, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin slymphoma. J Clin Oncol 1999 ; 17 : 1244-1253
23. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009 ; 27 : 4378-4384
24. Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas-final results of a randomized phase III study NHL 2-2003 on behalf of the Stil (Study Group Indolent Lymphomas, Germ an y). Blood 2010 ; 116(Suppl. 1) : Abstract 856
25. Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the Stil NHL1 study. J Clin Oncol 2012; 30(Suppl.): Abstract 3
26. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open label, phase 3 trial. Lancet 2010 ; 376 : 1164-1174
27. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/ refractory indolent and mantle cell non-Hodgkin slymphoma. Blood 2011 ; 117 : 2807-2812
28. Rummel MJ, Gregory SA. Bendamustine s emerging role in the management of lymphoid malignancies. Semin Hematol 2011 ; 48(Suppl. 1): S24-S36